PPARgamma expression in T cells as a marker of orthopedic infectious disease progression

PPARgamma expression in T cells as a marker of orthopedic infectious disease progression - -

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00016553

Enrollment

220

Registered

2019-02-27

Start date

2019-02-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M46.2 M46.3 M46.4 M46.1 M46.5 M00 M01 T84 M19

Interventions

Group 1: Patients with diagnosed joint / prosthesis infection: In this study, we aim to investigate the T cell PPARgamma expression of orthopaedic infectious patients to test whether it is regulated d

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Healthy test persons: men and women between the ages of 18 and 85; Spondylodiscitis: men and women between the ages of 18 and 85. Patients with diagnosed spondylodiscitis; Joint / prosthesis infection: men and women between the ages of 18 and 85. Patients with diagnosed joint / prosthesis infection; Surgical patients: men and women between the ages of 18 and 85. Patients with elective surgery without evidence of infection.

Exclusion criteria

Exclusion criteria: Age 85 years

Design outcomes

Primary

Measure	Time frame
Primary outcome: PPARgamma mRNA expression in CD3 positive t cells. For each sample, 10 ml of EDTA blood will be taken with the routine blood withdrawal. The blood sample will be used for the analysis of the T cell-specific mRNA PPARgamma expression. A total of 8 samples per patient will be examined. 4 blood samples from operative patients without infection and 2 blood samples from healthy donors will be taken and analyzed as control groups. The T-cell subpopulations will be enriched by magnetic separation. From these enriched cell populations, we will isolate RNA to determine the level of PPARgamma mRNA expression. The quantification (ng/cell) of PPARgamma mRNA (ng/cell) will be measured by quantitative PCR using an established PPARgamma plasmid standard.	—

Measure

Time frame

Primary outcome: PPARgamma mRNA expression in CD3 positive t cells. For each sample, 10 ml of EDTA blood will be taken with the routine blood withdrawal. The blood sample will be used for the analysis of the T cell-specific mRNA PPARgamma expression. A total of 8 samples per patient will be examined. 4 blood samples from operative patients without infection and 2 blood samples from healthy donors will be taken and analyzed as control groups. The T-cell subpopulations will be enriched by magnetic separation. From these enriched cell populations, we will isolate RNA to determine the level of PPARgamma mRNA expression. The quantification (ng/cell) of PPARgamma mRNA (ng/cell) will be measured by quantitative PCR using an established PPARgamma plasmid standard.

—

Secondary

Measure	Time frame
Secondary Outcome: The number of CD3 T cells and T cell subsets. The number of CD3 T cells and T cell subsets will be determined by FACS analysis as cells/µl. Secondary outcome: medical patient data. In addition, the clinical parameters of the patients are determined at the respective time points after the diagnosis of the disease or the elective surgery. This includes blood pressure, body temperature, heart rate, and patients’ clinical condition as well as medication.	—

Measure

Time frame

Secondary Outcome: The number of CD3 T cells and T cell subsets. The number of CD3 T cells and T cell subsets will be determined by FACS analysis as cells/µl. Secondary outcome: medical patient data. In addition, the clinical parameters of the patients are determined at the respective time points after the diagnosis of the disease or the elective surgery. This includes blood pressure, body temperature, heart rate, and patients’ clinical condition as well as medication.

—

Countries

Germany

Contacts

Public ContactMarco Brenneis

Orthopädische Universitätsklinik Friedrichsheim

m.brenneis@friedrichsheim.de069-6705-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026